Shares of TESARO, Inc. (NASDAQ:TSRO) have received an average recommendation of “Buy” from the twenty-six brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $176.67.

A number of equities analysts recently weighed in on the company. Janney Montgomery Scott set a $139.00 price target on TESARO and gave the stock a “hold” rating in a research note on Saturday, June 10th. Zacks Investment Research raised TESARO from a “sell” rating to a “hold” rating in a research note on Friday, March 31st. Cowen and Company set a $145.00 price target on TESARO and gave the stock a “hold” rating in a research note on Saturday, June 10th. Gabelli assumed coverage on TESARO in a research note on Friday. They issued a “buy” rating and a $175.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $164.00 price target (down previously from $200.00) on shares of TESARO in a research note on Wednesday, March 15th.

In related news, VP Edward C. English sold 8,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the sale, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 34.60% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new position in shares of TESARO during the fourth quarter valued at approximately $3,292,000. Dimensional Fund Advisors LP increased its position in shares of TESARO by 2.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 90,321 shares of the biopharmaceutical company’s stock valued at $12,146,000 after buying an additional 1,748 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of TESARO during the fourth quarter valued at approximately $502,000. Metropolitan Life Insurance Co. NY increased its position in shares of TESARO by 5.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 19,749 shares of the biopharmaceutical company’s stock valued at $2,656,000 after buying an additional 1,043 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in shares of TESARO by 18.2% in the fourth quarter. AQR Capital Management LLC now owns 46,697 shares of the biopharmaceutical company’s stock valued at $6,279,000 after buying an additional 7,174 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “TESARO, Inc. (NASDAQ:TSRO) Given Average Rating of “Buy” by Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/11/tesaro-inc-nasdaqtsro-given-average-rating-of-buy-by-analysts.html.

Shares of TESARO (NASDAQ:TSRO) traded down 0.17% during midday trading on Tuesday, reaching $132.42. 614,024 shares of the company were exchanged. TESARO has a 52-week low of $83.26 and a 52-week high of $192.94. The firm’s 50 day moving average is $146.21 and its 200-day moving average is $151.73. The company’s market capitalization is $7.13 billion.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The company’s revenue for the quarter was up 909.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.22) EPS. On average, equities analysts forecast that TESARO will post ($8.74) earnings per share for the current fiscal year.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.